<p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）在週三發佈給客户和投資者的研究報告中，分析師將其目標價從 35.00 美元上調至 46.00 美元，Benzinga 報道。該公司目前對這家生物技術公司的股票給予 “市場表現” 評級。Sanford C. Bernstein 的目標價意味着該公司股價相較於之前收盤價有 41.47% 的潛在下跌空間。</p>
<ul>
<li>想要在生物技術領域獲得多元化的上漲機會？查看 LABU</li>
</ul>
<p>其他一些分析師也對該股票發表了看法。B. Riley Financial 在 1 月 22 日的報告中將箭頭製藥的目標價從 61.00 美元上調至 101.00 美元，並給予該公司 “買入” 評級。摩根大通在 5 月 1 日的報告中開始覆蓋箭頭製藥的股票，給予 “增持” 評級和 88.00 美元的目標價。Piper Sandler 在 1 月 13 日的報告中重申了 “增持” 評級，並將箭頭製藥的目標價從 100.00 美元上調至 110.00 美元。加拿大皇家銀行在 5 月 8 日的報告中將箭頭製藥的目標價從 80.00 美元上調至 87.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Weiss Ratings 在 5 月 6 日的報告中重申了對箭頭製藥的 “持有（c-）” 評級。一位研究分析師給予該股票 “強烈買入” 評級，八位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價為 87.80 美元。</p>
<p><strong>閲讀我們關於箭頭製藥的最新股票報告</strong></p>
<h2>箭頭製藥的價格表現</h2>
<p>箭頭製藥的股票在週三的午盤交易中下跌 0.45 美元，達到 78.59 美元。該公司的交易量為 982,488 股，而其平均交易量為 2,587,857 股。該公司的流動比率為 6.23，速動比率為 6.23，債務與股本比率為 1.41。該公司的市值為 110.7 億美元，市盈率為-36.50，貝塔值為 1.28。該股票的 50 日簡單移動平均線為 65.12 美元，200 日簡單移動平均線為 61.17 美元。箭頭製藥的 1 年最低價為 14.30 美元，1 年最高價為 80.67 美元。</p>
<p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）在 5 月 7 日最後發佈了季度財報。這家生物技術公司報告本季度每股收益為-0.93 美元，超出分析師共識預期的-1.10 美元，超出幅度為 0.17 美元。該季度的營業收入為 7374 萬美元，而分析師預期為 7384 萬美元。箭頭製藥的淨利潤率為-48.38%，股本回報率為-55.09%。與去年同期相比，箭頭製藥的季度收入下降了 86.4%。去年同期，該公司每股收益為 2.75 美元。整體來看，股票研究分析師預測箭頭製藥在本年度的每股收益將為-3.04 美元。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，首席財務官 Daniel Joseph Apel 在 4 月 22 日的交易中出售了 13,095 股箭頭製藥的股票。股票以平均 71.35 美元的價格出售，總交易額為 934,328.25 美元。交易後，首席財務官直接持有該公司 162,905 股股票，價值 11,623,271.75 美元。這筆交易代表了他們持股比例的 7.44% 的減少。該銷售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税務扣繳義務。此外，內部人士 James C. Hamilton 在 4 月 23 日的交易中出售了 10,000 股箭頭製藥的股票。該股票以平均 75.00 美元的價格出售，總交易額為 750,000.00 美元。交易後，內部人士直接持有該公司 226,958 股股票，價值約 17,021,850 美元。這代表了他們持股比例的 4.22% 的減少。該銷售的 SEC 文件提供了更多信息。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去三個月中，內部人士共出售了 33,095 股公司股票，價值 2,326,228 美元。內部人士持有公司股票的比例為 3.60%。</p>
<h2>機構投資者對箭頭製藥的看法</h2>
<p>機構投資者最近增加或減少了對該股票的持股。Tsfg LLC 在第四季度購買了價值 25,000 美元的箭頭製藥新股份。First Horizon Corp 在第四季度購買了價值 32,000 美元的箭頭製藥新股份。WPG Advisers LLC 在第四季度將其在箭頭製藥的持股增加了 384.8%。WPG Advisers LLC 現在擁有 543 股該生物技術公司的股票，價值 36,000 美元，此前在上個季度又購買了 431 股。Hantz Financial Services Inc.在第四季度將其在箭頭製藥的持股增加了 177.1%。Hantz Financial Services Inc.現在擁有 737 股該生物技術公司的股票，價值 49,000 美元，此前在上個季度又購買了 471 股。最後，Elyxium Wealth LLC 在第四季度購買了價值 54,000 美元的箭頭製藥新股份。62.61% 的股票由機構投資者持有。</p>
<h2>關於箭頭製藥</h2>
<p>（獲取免費報告）</p>
<p>Arrowhead Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於 RNA 干擾（RNAi）治療藥物的發現、開發和商業化。自 2008 年成立以來，Arrowhead 利用其專有的遞送平台——內部稱為先進 RNAi 化合物（ARC）技術——來沉默患有遺傳性疾病的患者體內致病基因。該公司的方法旨在提供持久、針對性的治療，涵蓋多個治療領域。</p>
<p>該公司的產品管線包括多個處於不同開發階段的候選藥物。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比 Arrowhead Pharmaceuticals 更好的股票</li>
<li>D-Wave 的財報看起來疲軟，但投資者可能忽視了這一點</li>
<li>隨着 AI 反饋循環加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士賣出</li>
<li>Plug Power 開啓盈利模式</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資$1,000 在 Arrowhead Pharmaceuticals 嗎？</h2>
<p>在考慮 Arrowhead Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，以便在更廣泛的市場注意到之前……而 Arrowhead Pharmaceuticals 並不在名單上。</p>
<p>雖然 Arrowhead Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

箭頭制藥

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

IBBQ

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>Sanford C. Bernstein 將箭頭製藥（NASDAQ:ARWR）的目標股價從 35.00 美元上調至 46.00 美元，維持 “市場表現” 評級。這個新目標暗示與前一交易日收盤價相比有 41.47% 的潛在下跌空間。其他分析師的評級和目標股價各不相同，普遍評級為 “適度買入”，平均目標股價為 87.80 美元。箭頭製藥的股票最近交易價格為 78.59 美元，市值為 110.7 億美元，淨利潤率為 -48.38%</p>

<p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) had its price target upped by analysts at Sanford C. Bernstein from $35.00 to $46.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a &#34;market perform&#34; rating on the biotechnology company's stock. Sanford C. Bernstein's price target would indicate a potential downside of 41.47% from the company's previous close.</p>
<div class="lb-trans"><p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）在週三發佈給客户和投資者的研究報告中，分析師將其目標價從 35.00 美元上調至 46.00 美元，Benzinga 報道。該公司目前對這家生物技術公司的股票給予 “市場表現” 評級。Sanford C. Bernstein 的目標價意味着該公司股價相較於之前收盤價有 41.47% 的潛在下跌空間。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技術領域獲得多元化的上漲機會？查看 LABU</li>
</ul>
</div><p>A number of other analysts have also weighed in on the stock. B. Riley Financial raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 22nd. JPMorgan Chase &amp; Co. assumed coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They issued an &#34;overweight&#34; rating and a $88.00 price target for the company. Piper Sandler reaffirmed an &#34;overweight&#34; rating and set a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Royal Bank Of Canada lifted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $87.80.</p>
<div class="lb-trans"><p>其他一些分析師也對該股票發表了看法。B. Riley Financial 在 1 月 22 日的報告中將箭頭製藥的目標價從 61.00 美元上調至 101.00 美元，並給予該公司 “買入” 評級。摩根大通在 5 月 1 日的報告中開始覆蓋箭頭製藥的股票，給予 “增持” 評級和 88.00 美元的目標價。Piper Sandler 在 1 月 13 日的報告中重申了 “增持” 評級，並將箭頭製藥的目標價從 100.00 美元上調至 110.00 美元。加拿大皇家銀行在 5 月 8 日的報告中將箭頭製藥的目標價從 80.00 美元上調至 87.00 美元，並給予該股票 “跑贏大盤” 評級。最後，Weiss Ratings 在 5 月 6 日的報告中重申了對箭頭製藥的 “持有（c-）” 評級。一位研究分析師給予該股票 “強烈買入” 評級，八位分析師給予 “買入” 評級，三位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價為 87.80 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於箭頭製藥的最新股票報告</strong></p>
</div><h2>Arrowhead Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>箭頭製藥的價格表現</h2>
</div><p>Shares of Arrowhead Pharmaceuticals stock traded down $0.45 during midday trading on Wednesday, reaching $78.59. The company had a trading volume of 982,488 shares, compared to its average volume of 2,587,857. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $11.07 billion, a price-to-earnings ratio of -36.50 and a beta of 1.28. The stock has a fifty day simple moving average of $65.12 and a 200 day simple moving average of $61.17. Arrowhead Pharmaceuticals has a 1-year low of $14.30 and a 1-year high of $80.67.</p>
<div class="lb-trans"><p>箭頭製藥的股票在週三的午盤交易中下跌 0.45 美元，達到 78.59 美元。該公司的交易量為 982,488 股，而其平均交易量為 2,587,857 股。該公司的流動比率為 6.23，速動比率為 6.23，債務與股本比率為 1.41。該公司的市值為 110.7 億美元，市盈率為-36.50，貝塔值為 1.28。該股票的 50 日簡單移動平均線為 65.12 美元，200 日簡單移動平均線為 61.17 美元。箭頭製藥的 1 年最低價為 14.30 美元，1 年最高價為 80.67 美元。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.17. The business had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. Arrowhead Pharmaceuticals's revenue for the quarter was down 86.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.75 earnings per share. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -3.04 earnings per share for the current year.</p>
<div class="lb-trans"><p>箭頭製藥（NASDAQ:ARWR - 獲取免費報告）在 5 月 7 日最後發佈了季度財報。這家生物技術公司報告本季度每股收益為-0.93 美元，超出分析師共識預期的-1.10 美元，超出幅度為 0.17 美元。該季度的營業收入為 7374 萬美元，而分析師預期為 7384 萬美元。箭頭製藥的淨利潤率為-48.38%，股本回報率為-55.09%。與去年同期相比，箭頭製藥的季度收入下降了 86.4%。去年同期，該公司每股收益為 2.75 美元。整體來看，股票研究分析師預測箭頭製藥在本年度的每股收益將為-3.04 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company's stock, valued at $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 33,095 shares of company stock worth $2,326,228. Insiders own 3.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席財務官 Daniel Joseph Apel 在 4 月 22 日的交易中出售了 13,095 股箭頭製藥的股票。股票以平均 71.35 美元的價格出售，總交易額為 934,328.25 美元。交易後，首席財務官直接持有該公司 162,905 股股票，價值 11,623,271.75 美元。這筆交易代表了他們持股比例的 7.44% 的減少。該銷售在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税務扣繳義務。此外，內部人士 James C. Hamilton 在 4 月 23 日的交易中出售了 10,000 股箭頭製藥的股票。該股票以平均 75.00 美元的價格出售，總交易額為 750,000.00 美元。交易後，內部人士直接持有該公司 226,958 股股票，價值約 17,021,850 美元。這代表了他們持股比例的 4.22% 的減少。該銷售的 SEC 文件提供了更多信息。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去三個月中，內部人士共出售了 33,095 股公司股票，價值 2,326,228 美元。內部人士持有公司股票的比例為 3.60%。</p>
</div><h2>Institutional Investors Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對箭頭製藥的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. Tsfg LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $32,000. WPG Advisers LLC lifted its position in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 431 shares in the last quarter. Hantz Financial Services Inc. lifted its position in Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 471 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $54,000. 62.61% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該股票的持股。Tsfg LLC 在第四季度購買了價值 25,000 美元的箭頭製藥新股份。First Horizon Corp 在第四季度購買了價值 32,000 美元的箭頭製藥新股份。WPG Advisers LLC 在第四季度將其在箭頭製藥的持股增加了 384.8%。WPG Advisers LLC 現在擁有 543 股該生物技術公司的股票，價值 36,000 美元，此前在上個季度又購買了 431 股。Hantz Financial Services Inc.在第四季度將其在箭頭製藥的持股增加了 177.1%。Hantz Financial Services Inc.現在擁有 737 股該生物技術公司的股票，價值 49,000 美元，此前在上個季度又購買了 471 股。最後，Elyxium Wealth LLC 在第四季度購買了價值 54,000 美元的箭頭製藥新股份。62.61% 的股票由機構投資者持有。</p>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於箭頭製藥</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於 RNA 干擾（RNAi）治療藥物的發現、開發和商業化。自 2008 年成立以來，Arrowhead 利用其專有的遞送平台——內部稱為先進 RNAi 化合物（ARC）技術——來沉默患有遺傳性疾病的患者體內致病基因。該公司的方法旨在提供持久、針對性的治療，涵蓋多個治療領域。</p>
</div><p>The company's pipeline includes multiple candidates in various stages of development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同開發階段的候選藥物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
<li>Plug Power Flips The Switch On Profitability</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Arrowhead Pharmaceuticals 更好的股票</li>
<li>D-Wave 的財報看起來疲軟，但投資者可能忽視了這一點</li>
<li>隨着 AI 反饋循環加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士賣出</li>
<li>Plug Power 開啓盈利模式</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Arrowhead Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Arrowhead Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在買入的股票，以便在更廣泛的市場注意到之前……而 Arrowhead Pharmaceuticals 並不在名單上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Arrowhead Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00

Market Beat

Invesco Nasdaq Biotechnology ETF

摩根大通

Piper Sandler Cos

加拿大皇家銀行

Weis Markets

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

桑福德·C·伯恩斯坦將 ArrowHead Pharma（NASDAQ:ARWR）的目標股價上調至 46.00 美元